Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of TM208 on non-small cell lung cancer xenograft

doi:10.5246/jcps.2016.07.055

Journal of Chinese Pharmaceutical Sciences ›› 2016, Vol. 25 ›› Issue (7): 502-511.DOI: 10.5246/jcps.2016.07.055

• Original articles • Previous Articles Next Articles

Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of TM208 on non-small cell lung cancer xenograft

Ming Hua¹, Xiwei Ji^1,3, Runtao Li², Shuangmin Ji¹, Jian Li¹, Qingyu Yao¹, Lijie Wang¹, Fangran Hao¹, Wei Lu^1,2, Tianyan Zhou^1,2*

1. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing 100191, China
3. Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100191, China

Received:2016-04-07 Revised:2016-05-03 Online:2016-07-19 Published:2016-05-15
Contact: Tel.: +86-010-82805937, Fax: +86-010-82801717, E-mail: tianyanzhou@bjmu.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 81273583).

Abstract

Abstract:

In the present study, we aimed to investigate the anticancer effect of TM208 (4-methylpiperazine-1-carbodithioc-acid-3-cyano-3,3-diphenylpropyl ester hydrochloride) on non-small cell lung cancer (NSCLC). Moreover, pharmacokinetic-pharmacodynamic (PK-PD) model was developed to describe and simulate the time-course of the drug response in A549 xenograft model. The inhibition rates of two treatment groups (TM208 100 mg/kg group and TM208 150 mg/kg group) in A549 xenograft model were first compared with both vehicle and positive control groups. Subsequently, natural tumor growth model was built and finally PK-PD model was established based on the PD data of the vehicle control group and TM208 treatment groups. In addition, the model was further evaluated, and the anti-cancer efficacy under different regimens was simulated. Our results showed that NSCLC was one potential indication of TM208 and TM208 150 mg/kg QD would be an effective regimen. For parameters about tumor growth, the initial volume was 0.134 cm³ and the growth rate was 0.0869 day^–¹. For parameters about drug efficacy, the killing factor was 0.174 mL/μg/dand average transit rate among transit compartments was 0.173 day^–¹. Among various regimens in the step of simulation, TM208 900 mg/kg QW, which was a hypothetical regimen without experimental data support yet, showed similar anticancer effect compared with TM208 150 mg/kg QD. In conclusion, the anti-cancer effect of TM208 on NSCLC was demonstrated by the pre-clinical experiment and confirmed by the developed PK-PD model. Moreoever, results from model simulation would be helpful for further translational research of TM208.

Key words: Pharmacokinetic-pharmacodynamic model, TM208, Non-small cell lung cancer

CLC Number:

R969

Supporting:

Ming Hua, Xiwei Ji, Runtao Li, Shuangmin Ji, Jian Li, Qingyu Yao, Lijie Wang, Fangran Hao, Wei Lu, Tianyan Zhou. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of TM208 on non-small cell lung cancer xenograft[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(7): 502-511.

References

[1] Aboul-Fadl, T.; El-Shorbagi, A. Eur. J. Med. Chem. 1996, 31, 165-169.
[2] Len, C.; Boulogne-Merlot, A.S.; Postel, D.; Ronco, G.; Villa, P.; Goubert, C.; Jeufrault, E.; Mathon, B.; Simon, H. J. Agric. Food Chem. 1996, 44, 2856-2858.
[3] Hidaka, S.; Funakoshi, T.; Shimada, H.; Tsuruoka, M.; Kojima, S. J. Appl. Toxicol. 1995, 15, 267-273.
[4] Guo, W.; Ran, F.X.; Wang, R.Q.; Cui, J.R.; Li, R.T.; Cheng, T.M.; Ge, Z.M. Chin. J. Clin. Pharm. Ther. 2004, 9, 59-62.
[5] Lin, J.; Bo, X.; Guo, W.; Ge, Z.M.; Li, R.T.; Cui, J.R. J. Chin. Pharm. Sci. 2011, 20, 615-626.
[6] Ji, X.W.; Li, R.T.; Li, Z.Q.; Li, L.; Shao, X.Y.; Wang, S.Y.; Yuan, Y.; Zhou, T.Y.; Lu, W. Acta Pharm. Sin. 2014, 35, 239-247.
[7] Ji, X.W.; Chen, G.P.; Song, Y.; Hua, M.; Wang, L.J.; Li, L.; Yuan, Y.; Wang, S.Y.; Zhou, T.Y.; Lu, W. Acta Pharm. Sin. 2015, 36, 1246-1255.
[8] World Health Organization, International Agency for Research on Cancer. GLOBOCAN: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer. Available at http://globocan.iarc.fr/Default.aspx. Accessed: May 15, 2014.
[9] American Cancer Society. Cancer Facts & Figures 2016. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079. pdf. Accessed: March 30, 2016.
[10] Curran, W.J.; Paulus, R.; Langer, C.J.; Komaki, R.; Lee, J.S.; Hauser, S.; Movsas, B.; Wasserman, T.; Rosenthal, S.A.; Gore, E.; Machtay, M.; Sause, W.; Cox, J.D. J. Natl. Cancer Inst. 2011, 103, 1452-1460.
[11] Arriagada, R.; Bergman, B.; Dunant, A.; Le Chevalier, T.; Pignon, J.P.; Vansteenkiste, J. N. Engl. J. Med. 2004, 350, 351-360.
[12] Simeoni, M.; Magni, P.; Cammia, C.; De Nicolao, G.; Croci, V.; Pesenti, E.; Germani, M.; Poggesi, I.; Rocchetti, M. Cancer Res. 2004, 64, 1094-1101.
[13] Lobo, E.D.; Balthasar, J.P. AAPS PharmSci. 2002, 4, 212-222.
[14] Breimer, D.D. Pharm. Res. 2008, 25, 2720-2722.
[15] Peck, C.C.; Barr, W.H.; Benet, L.Z.; Collins, J.; Desjardins, R.E.; Furst, D.E.; Harter, J.G.; Levy, G.; Ludden, T.; Rodman, J.H.; Sanathanan, L. J. Pharm. Sci. 1992, 81, 605-610.
[16] Li, M.; Li, H.; Cheng, X.; Wang, X.; Li, L.; Zhou, T.; Lu, W. Pharm. Res. 2013, 30, 1400-1408.
[17] Yuan, Y.; Zhou, X.; Ren, Y.P.; Zhou, S.P.; Wang, L.J.; Ji, S.M.; Hua, M.; Li, L.; Lu, W.; Zhou, T.Y. J. Pharm. Sci. 2015, 104, 4399-4408.
[18] Ji, X.W.; Ji, S.M.; Li, R.T.; Wu, K.H.; Zhu, X.; Zhou, T.Y.; Lu, W. Acta Pharmacol. Sin. 2016, in press.
[19] Yamazaki, S.; Nguyen, L.; Vekich, S.; Shen, Z.; Yin, M.J.; Mehta, P.P.; Kung, P.P.; Vicini, P. J. Pharmacol. Exp. Ther. 2011, 338, 964-973.
[20] Klijn, J.G.M.; Berns, P.M.J.J.; Schmitz, P.I.M.; Foekens, J.A. Endocr. Rev. 1992, 13, 3-17.
[21] Bayliss, J.; Hilger, A.; Vishnu, P.; Diehl, K.; El-Ashry, D. Clin. Cancer Res. 2007, 13, 7029-7036.
[22] Hsu, L.H.; Liu, K.J.; Tsai, M.F.; Wu, C.R.; Feng. A.C.; Chu, N.M.; Kao, S.H. Cancer Sci. 2014, 106, 51-59.
[23] Salphati, L.; Wong, H.; Belvin, M.; Bradford, D.; Edgar, K.A.; Prior, W.W.; Sampath, D.; Wallin, J.J. Drug Metab. Dispos. 2010, 39, 1436-1442.
[24] Yamazaki, S.; Lam, J.L.; Zou, H.Y.; Wang, H.; Smeal, T.; Vicini, P. Drug Metab. Dispos. 2015, 43, 54-62.
[25] Rocchetti, M.; Simeoni, M.; Pesenti, E.; De Nicolao, G.; Poggesi, I. Eur. J. Cancer. 2007, 43, 1862-1868.
[26] Rocchetti, M.; Germani, M.; Bene, F.D.; Poggesi, I.; Magni, P.; Pesenti, E.; Nicolao, G.D. Cancer Chemother. Phgroupacol. 2013, 71, 1147-1157.
[27] Koch, G.; Walz, A.; Lahu, G.; Schropp, J. J. Pharmacokinet. Pharmacodyn. 2009, 36, 179-197.
[28] Goteti, K.; Garner, C.E.; Utley, L.; Dai, J.; Ashwell, S.; Moustakas, D.T.; Gönen, M.; Schwartz, G.K.; Kern, S.E.; Zabludoff, S.; Brassil, P.J. Cancer Chemother. Pharmacol. 2010, 66, 245-254.
[29] Ji, X.W.; Chen, Y.; Li, R.T.; Zhou, T.Y.; Lu, W. Biomed Chromatogr. 2012, 26, 1196-1201.

Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of TM208 on non-small cell lung cancer xenograft

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 253-263.
[2]	Shen Lin, Xin Rao, Yiyuan Li, Xiuhua Weng, Changlian Wang. Cost-effectiveness analysis of second-line chemotherapy strategies for patients with advanced non-squamous non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 542-553.
[3]	Zhenzhen Mou, Siyuan Wang, Qinghong Su, Yin Yuan, Jingyun Li, Lijie Wang, Qingyu Yao, Shuangmin Ji, Wei Lu, Tianyan Zhou. Cabozantinib enhances the response of NSCLC cells with wild-type EGFR to erlotinib and pharmacodynamic modeling of their sequential combinations [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(11): 799-813.
[4]	De-Tao Kong, Xiao-Mei Ling^, Fang-Bin Han, Jing-Li Gong, Ze-Mei Ge, Run-Tao Li, Jing-Rong Cui^*. Identification of the metabolite and cytochrome P450 isoforms involved in rat liver microsomal metabolism of TM208 [J]. , 2008, 17(1): 30-34.